Skip to main
AGEN

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Agenus Inc. is well-positioned for growth due to its diverse and promising product pipeline, which includes innovative therapies aimed at harnessing the immune system to combat cancer and infections. The company's potential to generate additional revenue from the compassionate use of its antibody candidates, botensilimab and balstilimab, is bolstered by the provision of real-world clinical evidence that supports their efficacy in critical cancer indications, such as triple negative breast cancer and ER+ breast cancer. Furthermore, positive ex-US regulatory sentiment regarding these therapies enhances the company's outlook, indicating potential for broader market acceptance and validation of their clinical benefits.

Bears say

Agenus Inc faces several significant risks that contribute to a negative outlook on its stock. The potential emergence of safety signals in clinical programs, combined with the possibility of lower-than-expected efficacy in studies, undermines investor confidence in the company's ability to deliver viable products. Additionally, concerns regarding regulatory decisions, increased commercial competition, financing requirements, and the adequacy of intellectual property protections further exacerbate the challenges facing Agenus's pipeline and market position.

Agenus (AGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Agenus (AGEN) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.